A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8(+) T cell responses

PD-1 and CTLA-4 antibodies offer great hope for cancer immunotherapy. However, many patients are incapable of responding to PD-1 and CTLA-4 blockade and show low response rates due to insufficient immune activation. The combination of checkpoint blockers has been proposed to increase the response ra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Acta Pharm Sin B
Main Authors: Zhai, Wenjie, Zhou, Xiuman, Wang, Hongfei, Li, Wanqiong, Chen, Guanyu, Sui, Xinghua, Li, Guodong, Qi, Yuanming, Gao, Yanfeng
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7332792/
https://ncbi.nlm.nih.gov/pubmed/32642411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.apsb.2020.01.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados